Asia Pacific Genome Editing Market Outlook to 2028

Asia Pacific Genome Editing Market Overview

In 2023, the Asia Pacific genome editing market was valued at USD 0.93 billion. The market is driven by advancements in CRISPR technology, rising demand for precision medicine, and government initiatives supporting biotechnology innovation. Genome editing technologies are playing an increasingly important role in healthcare, agriculture, and environmental sustainability across the region.

Key players in the Asia-Pacific genome editing market include CRISPR Therapeutics, Thermo Fisher Scientific, Editas Medicine, and Sangamo Therapeutics. These companies dominate the market through their advanced gene editing tools and strategic partnerships. Additionally, regional firms like Takara Bio in Japan play a significant role due to their local presence and innovative research capabilities.

Shanghai, Beijing, Tokyo, and Bengaluru are dominant cities driving the genome editing market in Asia-Pacific. These cities host prominent biotechnology hubs, benefiting from government-funded research initiatives and robust academic-industry collaborations. For example, Shanghai and Beijing have invested heavily in research parks and facilities, supporting biotech innovation.

In January 2024, China's BGI Genomics announced a groundbreaking collaboration with the Australian government to establish a genome editing center in Sydney. The facility will focus on applying CRISPR technology to agriculture, enhancing crop resilience. This collaboration, funded with an initial USD 50 million investment, reflects the growing importance of cross-border partnerships in leveraging genome editing technology in various sectors beyond healthcare, including agriculture and environmental sustainability.

Asia Pacific Genome Editing Market Segmentation

By Technology: The Asia Pacific genome editing market is segmented by technology into CRISPR, TALENs, and ZFN. In 2023, CRISPR dominated the market due to its widespread use in healthcare and agricultural applications. CRISPRs cost-effectiveness and high precision have made it the dominant technology in genome editing.

By Application: The Asia Pacific genome editing market is segmented by application into human therapeutics, agriculture, and research & development. Human therapeutics dominated the market in 2023, driven by increasing investments in gene therapies for genetic disorders and cancer treatments. The growing demand for personalized medicine and advancements in gene therapies are key factors for its dominance.

By Region: The Asia Pacific genome editing market is segmented into China, Japan, South Korea, India, and Australia. China led the market in 2023, driven by significant government investments in biotechnology and advanced healthcare research. Chinas focus on reducing its reliance on foreign technologies and developing indigenous solutions has strengthened its position in the genome editing sector.

Asia Pacific Genome Editing Market Competitive Landscape

Company

Establishment Year

Headquarters

CRISPR Therapeutics

2013

Zug, Switzerland

Thermo Fisher Scientific

1956

Waltham, Massachusetts

Editas Medicine

2013

Cambridge, Massachusetts

Sangamo Therapeutics

1995

Brisbane, California

Takara Bio

1967

Shiga, Japan

Thermo Fisher Scientific: In2023, Thermo Fisher Scientific released new gene synthesis and genome editing products tailored for the Asia Pacific market. This expansion aims to meet the growing demand for synthetic biology applications in the region, particularly in research and development initiatives related to genetic diseases and cancer therapies.

Sangamo Therapeutics: On May 9, 2024, Sangamo Therapeutics presented its new Modular Integrase Technology (MINT) platform, designed to enable large-scale genome editing. This platform utilizes a serine recombinase to integrate large DNA constructs into the genome, potentially addressing challenges in precise gene integration.

Asia Pacific Genome Editing Industry Analysis

Asia Pacific Genome Editing Market Growth Drivers

Rising Demand for Precision Medicine: The increasing prevalence of genetic disorders and the demand for personalized medicine are propelling the growth of the genome editing market. By 2028, the market is projected to reach USD 1.96 billion, reflecting the growing need for targeted therapies that address specific genetic conditions.

Trials for EDIT-301: Editas Medicine is actively advancing its clinical trials for EDIT-301, which is focused on treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). As of August 2, 2023, the company was on track to dose a total of 20 patients in the RUBY trial for SCD and provide a clinical update by the end of the year. They also commenced parallel patient dosing in the EDITHAL trial for TDT, with updates expected by year-end 2023

Agricultural Innovations: The application of genome editing in agriculture, particularly in improving crop resilience and yield, is a significant growth driver. In 2024, the market is expected to benefit from initiatives in countries like India and China, where genome editing is being used to enhance food security in response to climate change.

Asia Pacific Genome Editing Market Challenges

Regulatory and Ethical Concerns: Ethical concerns related to human gene editing continue to pose challenges in countries like China. In 2023, the Chinese government introduced new regulations requiring stricter oversight of genome editing research involving human subjects, slowing the approval process for clinical trials and limiting the pace of innovation.

Lack of Skilled Workforce: The shortage of trained professionals in genome editing is a growing challenge in developing markets like India and Vietnam. According to the Indian Council of Medical Research, the country faces a significant gap in skilled talent, requiring an additional 10,000 professionals by 2025 to meet the growing demand for genetic research.

Asia Pacific Genome Editing Market Government Initiatives

India's New Guidelines for Gene-Edited Plants (2022): India released new guidelines in March 2022 that deregulate genome-edited plants (SDN1 and SDN2 products without transgenes) while regulating SDN3 products as GMOs. This regulatory framework aims to encourage innovation in agricultural biotechnology and facilitate the development of crops that can address food security challenges.

Philippines' Regulatory System for GM Crops: The Philippines has established an operational regulatory system for GM crops and has released guidelines for plant products derived from new breeding techniques (NBTs). This flexible regulatory framework supports the development of genome-edited crops, positioning the Philippines as a leader in agricultural biotechnology in Southeast Asia

Asia Pacific Genome Editing Future Market Outlook

The Asia Pacific genome editing market is expected to grow significantly by 2028, driven by advancements in CRISPR technology and the expanding application of genome editing in healthcare, agriculture, and environmental sustainability.

Future Market Trends

Expansion of Genome Editing in Agriculture: Over the next five years, CRISPR applications in agriculture will expand, particularly in China and India. These technologies will improve crop resilience, making them more resistant to environmental challenges. Governments are likely to increase funding to support sustainable agricultural practices.

Rising Adoption of Gene Therapies in Cancer Treatment: Personalized gene therapies targeting cancer will become more common across the region by 2028. Japan and South Korea will lead the charge in integrating genome editing into oncology treatment plans, driven by the growing demand for precision medicine solutions.
Please Note: It will take 5-7 business days to complete the report upon order confirmation